Integrin alpha v beta 6 targeting ligands, conjugates, compositions and uses thereof
By developing ligands and conjugates targeting integrin αvβ6, the problem of difficult to effectively target and regulate the expression of integrin αvβ6 in the prior art is solved, and the potential diagnosis and treatment of related diseases are achieved.
CN120192313APending Publication Date: 2025-06-24RIGERNA THERAPEUTICS (BEIJING) CO LTD
Patent Information
- Application Number
- CN202311787123.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-22
- Publication Date
- 2025-06-24
AI Technical Summary
Technical Problem
The prior art is difficult to effectively target and regulate the expression of integrin αvβ6, which limits the diagnosis and treatment of related diseases.
Method used
A ligand targeting integrin αvβ6 was developed and targeted delivery of cells expressing integrin αvβ6 was achieved by binding to a double-stranded oligonucleotide to form a conjugate.
Benefits of technology
The specific delivery of functional groups to cells expressing integrin αvβ6 is achieved, with potential diagnostic and therapeutic applications.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120192313A_ABST
Abstract
The invention relates to a ligand targeting integrin alpha v beta 6, a conjugate, a composition and application thereof, and belongs to the technical field of small nucleic acid drug delivery. The ligand provided by the invention can target the integrin alpha v beta 6, and functional groups can be specifically delivered to cells and / or tissues expressing the integrin alpha v beta 6 by introducing the ligand into double-stranded oligonucleotide, so that the purpose of disease diagnosis and / or treatment is achieved.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
WO2019010274A1